You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Phase I study evaluating the treatment of patients with locally advanced pancreatic cancer with carbon ion radiotherapy: the PHOENIX-01 trial
|
|---|---|
| Published in |
BMC Cancer, September 2013
|
| DOI | 10.1186/1471-2407-13-419 |
| Pubmed ID | |
| Authors |
Stephanie E Combs, Daniel Habermehl, Meinhard Kieser, Constantin Dreher, Jens Werner, Renate Haselmann, Oliver Jäkel, Dirk Jäger, Markus W Büchler, Jürgen Debus |
| Abstract |
Treatment options for patients with locally advanced pancreatic cancer include surgery, chemotherapy as well as radiotherapy. In many cases, surgical resection is not possible, and therefore treatment alternatives have to be performed. Chemoradiation has been established as a convincing treatment alternative for locally advanced pancreatic cancer. Carbon ions offer physical and biological characteristics. Due to their inverted dose profile and the high local dose deposition within the Bragg peak precise dose application and sparing of normal tissue is possible. Moreover, in comparison to photons, carbon ions offer an increased relative biological effectiveness (RBE), which can be calculated between 1.16 and 2.46 depending on the pancreatic cancer cell line as well as the endpoint analyzed. Japanese Data on the evaluation of carbon ion radiation therapy showed promising results for patients with pancreatic cancer. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 52 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 2 | 4% |
| United Kingdom | 1 | 2% |
| Germany | 1 | 2% |
| Unknown | 48 | 92% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 9 | 17% |
| Other | 7 | 13% |
| Researcher | 7 | 13% |
| Student > Bachelor | 4 | 8% |
| Student > Master | 4 | 8% |
| Other | 8 | 15% |
| Unknown | 13 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 20 | 38% |
| Physics and Astronomy | 7 | 13% |
| Nursing and Health Professions | 3 | 6% |
| Agricultural and Biological Sciences | 3 | 6% |
| Business, Management and Accounting | 1 | 2% |
| Other | 4 | 8% |
| Unknown | 14 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 September 2013.
All research outputs
#20,202,510
of 22,721,584 outputs
Outputs from BMC Cancer
#6,489
of 8,268 outputs
Outputs of similar age
#172,825
of 197,557 outputs
Outputs of similar age from BMC Cancer
#73
of 83 outputs
Altmetric has tracked 22,721,584 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,268 research outputs from this source. They receive a mean Attention Score of 4.3. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 197,557 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 83 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.